Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients

B. Rubio-Viqueira, M. Hidalgo

Research output: Contribution to journalArticle

Abstract

It is estimated that the development of a new anticancer agent costs US$800 million to 1 billion and takes more than a decade between conception and approval. However, 90% of novel antineoplastic drugs fail in the clinic despite evidence of antitumor efficacy in classical preclinical models. This raises serious concerns as to whether such models are predictive of drug efficacy in humans, particularly in the current era of new targeted therapies, and supports the development of alternative approaches.

Original languageEnglish (US)
Pages (from-to)217-221
Number of pages5
JournalClinical Pharmacology and Therapeutics
Volume85
Issue number2
DOIs
StatePublished - Feb 2009

Fingerprint

Heterografts
Antineoplastic Agents
Pharmaceutical Preparations
Neoplasms
Costs and Cost Analysis
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. / Rubio-Viqueira, B.; Hidalgo, M.

In: Clinical Pharmacology and Therapeutics, Vol. 85, No. 2, 02.2009, p. 217-221.

Research output: Contribution to journalArticle

@article{339693a8b14b4ad09bab8958adfdcd4d,
title = "Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients",
abstract = "It is estimated that the development of a new anticancer agent costs US$800 million to 1 billion and takes more than a decade between conception and approval. However, 90{\%} of novel antineoplastic drugs fail in the clinic despite evidence of antitumor efficacy in classical preclinical models. This raises serious concerns as to whether such models are predictive of drug efficacy in humans, particularly in the current era of new targeted therapies, and supports the development of alternative approaches.",
author = "B. Rubio-Viqueira and M. Hidalgo",
year = "2009",
month = "2",
doi = "10.1038/clpt.2008.200",
language = "English (US)",
volume = "85",
pages = "217--221",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients

AU - Rubio-Viqueira, B.

AU - Hidalgo, M.

PY - 2009/2

Y1 - 2009/2

N2 - It is estimated that the development of a new anticancer agent costs US$800 million to 1 billion and takes more than a decade between conception and approval. However, 90% of novel antineoplastic drugs fail in the clinic despite evidence of antitumor efficacy in classical preclinical models. This raises serious concerns as to whether such models are predictive of drug efficacy in humans, particularly in the current era of new targeted therapies, and supports the development of alternative approaches.

AB - It is estimated that the development of a new anticancer agent costs US$800 million to 1 billion and takes more than a decade between conception and approval. However, 90% of novel antineoplastic drugs fail in the clinic despite evidence of antitumor efficacy in classical preclinical models. This raises serious concerns as to whether such models are predictive of drug efficacy in humans, particularly in the current era of new targeted therapies, and supports the development of alternative approaches.

UR - http://www.scopus.com/inward/record.url?scp=58549118535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58549118535&partnerID=8YFLogxK

U2 - 10.1038/clpt.2008.200

DO - 10.1038/clpt.2008.200

M3 - Article

C2 - 19005462

AN - SCOPUS:58549118535

VL - 85

SP - 217

EP - 221

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -